Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 20/20 | 1.00 |
| ▸ | CNR1 | P21554 | 4/20 | 0.85 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10048929 | 0.92 | CNR2 (1.00) | CNR2CNR1KCNH2 | |
| SCHEMBL10048920 | 0.89 | CNR2 (0.81) | CNR2CNR1KCNH2 | |
| SCHEMBL10048921 | 0.89 | CNR2 (0.80) | CNR2CNR1KCNH2 | |
| SCHEMBL10048862 | 0.87 | CNR2 (1.00) | CNR2CNR1KCNH2 | |
| SCHEMBL10048938 | 0.86 | CNR2 (0.81) | CNR2CNR1 | |
| SCHEMBL10048856 | 0.85 | CNR2 (1.00) | CNR2CNR1KCNH2 | |
| SCHEMBL3998237 | 0.85 | CNR2 (1.00) | CNR2CNR1KCNH2 | |
| SCHEMBL10048829 | 0.85 | CNR2 (0.85) | CNR2CNR1KCNH2 | |
| SCHEMBL13605878 | 0.84 | CNR2 (0.73) | CNR2CNR1KCNH2 | |
| SCHEMBL10048876 | 0.84 | CNR2 (1.00) | CNR2CNR1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2142531-B1 | BENZIMIDAZOLE CANNABINOID AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2015-07-08 | — | — | EP | disclosed |
| US-8193369-B2 | Benzimidazole cannabinoid agonists | JANSSEN PHARMACEUTICA NV (BE) | 2012-06-05 | — | — | US | disclosed |
| US-8193369-B2 | Benzimidazole cannabinoid agonists | JANSSEN PHARMACEUTICA NV (BE) | 2012-06-05 | — | — | US | disclosed |
| US-20100041702-A1 | BENZIMIDAZOLE CANNABINOID AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2010-02-18 | — | — | US | disclosed |
| US-20100041702-A1 | BENZIMIDAZOLE CANNABINOID AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2010-02-18 | — | — | US | disclosed |
| WO-2008119694-A1 | BENZIMIDAZOLE CANNABINOID AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041702-A1 | BENZIMIDAZOLE CANNABINOID AGONISTS | CNR1, CNR2, GPR18 | CNR2 2/4885CNR1 1/4885KCNH2 1838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.